Skip to main content

Table 1 Demographics. Adult/adolescent study

From: Arbaclofen in fragile X syndrome: results of phase 3 trials

Group/characteristic Placebo (N = 63) Arbaclofen (N = 62) Total (N = 125)
Mean age (SD) 18.7 (7.22) 19.0 (6.73) 18.9 (6.96)
Age group (adolescents age 12–17) 36 (57.1%) 31 (50.0%) 67 (53.6%)
Gender (males) 49 (77.8%) 50 (80.6%) 99 (79.2%)
 Race/ethnicity    
 White non-hispanic 50 (79%) 47 (76%) 97 (77%)
 White hispanic 4 (6.5%) 5 (8.1%) 9 (7.2%)
 African American 6 (9.5%) 5 (8.1%) 11 (8.8%)
 Asian 1 (1.6%) 1 (1.6%) 2 (1.6%)
 Other 2 (3.2%) 4 (6.5%) 6 (4.8%)
Concomitant medications    
 Any psychotropic medications 40 (63.5%) 35 (56.5%) 75 (60.0%)
 Antipsychotics 11 (17.4%) 14 (22.6%) 25 (20.0%)
 None 23 (36.5%) 27 (43.5%) 50 (40.0%)
DSM-IV diagnosis of ASD 45 (71.4%) 46 (74.2%) 91 (72.8%)
Mean ABC-CFX Social Avoidance score (SD) 7.9 (3.48) 7.6 (3.17)